ALLR Stock — Allarity Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.21

Market cap

$19.3M

Cash

$17.0M

Enterprise value

$23.2M

Balance sheet

Cash	$17.0M
Debt	$20.9M
Net cash	-$3.9M
Enterprise value	$23.2M
Basic shares	15.9M shares
Fully diluted shares	17.4M shares
Fully diluted market cap	$21.0M
Cash per share	$1.07

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ALLR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24	2X-121	Phase 2	Advanced Ovarian Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Stenoparib

Phase 2 · Active Modality: oral small molecule

Aliases E7449

Target PARP1/2 and tankyrases (WNT pathway)

Partnerships Eisai Pharmaceuticals: in-licensed exclusive worldwide rights; substantial development milestones and royalties on future sales upon marketing approval

Indications

Platinum-resistant ovarian cancer (Phase 2)
Relapsed small cell lung cancer (with temozolomide) (Phase 2)

Status note Company's sole remaining candidate; dovitinib, Irofulven and LiPlaCis were terminated and are no longer part of the portfolio. Two active Phase 2 studies: PROC randomized 2-dose trial (40 pts, initiated June 2025, enrolling) with stenoparib-DRP companion diagnostic (FDA IDE approved); relapsed SCLC trial with temozolomide, fully funded by the US Veteran's Administration, opened for enrollment January 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	2X-121
Lead indication	Advanced Ovarian Cancer
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT03878849	Phase 2	Recruiting	Sponsor	Allarity Therapeutics	—	Advanced Ovarian Cancer	—
NCT03877796	Not disclosed	Recruiting	Sponsor	Allarity Therapeutics	—	Ovarian Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Allarity Therapeutics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ALLR — Allarity Therapeutics Inc.